Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.67
$0.491.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.17% | 11.41% | 9.62% | 7.39% | 8.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.17% | 11.41% | 9.62% | 7.39% | 8.00% |
| Cost of Revenue | 9.02% | 4.78% | -1.16% | -2.07% | -4.43% |
| Gross Profit | 18.49% | 12.50% | 11.49% | 9.08% | 10.32% |
| SG&A Expenses | 48.55% | 23.44% | 2.51% | -3.43% | -6.36% |
| Depreciation & Amortization | 30.42% | 13.41% | -2.95% | -6.74% | -4.80% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.13% | 15.60% | -0.37% | -4.42% | -5.36% |
| Operating Income | -12.84% | 3.15% | 33.62% | 38.78% | 47.02% |
| Income Before Tax | -49.91% | 30.15% | 502.91% | 2,407.76% | 525.08% |
| Income Tax Expenses | -42.18% | 6.53% | 222.65% | 719.50% | 3,143.89% |
| Earnings from Continuing Operations | -52.95% | 43.68% | 882.63% | 995.02% | 417.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.95% | 43.68% | 882.63% | 995.02% | 417.77% |
| EBIT | -12.84% | 3.15% | 33.62% | 38.78% | 47.02% |
| EBITDA | 5.42% | 7.62% | 15.99% | 15.83% | 19.72% |
| EPS Basic | -51.97% | 45.89% | 933.96% | 1,019.27% | 428.88% |
| Normalized Basic EPS | -19.80% | 15.14% | 91.66% | 117.34% | 136.81% |
| EPS Diluted | -51.56% | 44.37% | 1,599.65% | 809.00% | 386.12% |
| Normalized Diluted EPS | -17.61% | 9.94% | 71.28% | 83.27% | 87.68% |
| Average Basic Shares Outstanding | -3.33% | -4.36% | -5.10% | -4.23% | -2.18% |
| Average Diluted Shares Outstanding | -8.43% | 0.99% | 6.84% | 13.65% | 22.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |